Modest efficacy of first-generation FLT3 inhibitors (e.g., lestaurtinib, midostaurin, sorafenib, sunitinib) in adults with relapsed AML has been reported, both as monotherapy and in conjunction with cytotoxic chemotherapy (48–52). The gene discussed is FLT3; the disease is acute myeloid leukemia.